查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
2023年至2028年睡眠障碍治疗市场预测
市场调查报告书
商品编码
1410055

2023年至2028年睡眠障碍治疗市场预测

Sleep Disorder Treatment Market - Forecasts from 2023 to 2028
出版日期: | 出版商: Knowledge Sourcing Intelligence | 英文 140 Pages | 商品交期: 最快1-2个工作天内

价格
简介目录

睡眠障碍治疗市场预计将从2021年的145.1亿美元成长到2028年的301.02亿美元，复合年增长率为10.99%。

睡眠障碍的治疗方法有很多种，取决于其性质和根本原因。然而，治疗通常涉及医疗干预和用餐调整的组合。由于药物、忧郁症和忧郁症增加等许多潜在因素导致睡眠障碍盛行率不断增加，正在推动睡眠障碍治疗市场的成长。此外，饮酒量的增加和气喘患者数量的增加预计将进一步推动睡眠障碍治疗市场的发展。

睡眠障碍增加

由于药物、频尿等多种因素，全球范围内睡眠障碍的数量不断增加，这是睡眠障碍治疗市场的主要成长动力。例如，世界经济论坛估计，2019 年，全球整体62% 的成年人认为自己晚上睡眠不足。此外，根据睡眠协会的数据，到 2022 年，多达 7,000 万美国人将遭受睡眠问题。根据睡眠基金会 2022 年的一项调查，51.2% 的睡眠不足者声称他们的家庭有睡眠问题。此外，据睡眠医生称，失眠是美国最常见的睡眠障碍，影响着约三分之二的美国成年人。睡眠障碍的增加以及嗜睡和易怒等负面影响预计将推动睡眠障碍治疗市场的发展。

忧郁症和焦虑增加

失眠，或入睡或保持睡眠困难，是忧郁症的典型症状之一。此外，心理或身体创伤、代谢问题和其他健康问题也可能导致睡眠障碍。因此，人们的忧郁症症状正在增加，这对睡眠障碍治疗市场产生了积极影响。根据世界卫生组织估计，全世界有 5% 的成年人患有忧郁症，相当于约 2.8 亿人。忧郁症对美国的死亡率、发病率、残疾和经济支出有重大影响。例如，据 CDC 称，2020 年，18.5% 的美国成年人被诊断出患有忧郁症。

气喘患者和酒精摄取量增加

气喘药物的刺激作用和其他医疗状况（例如睡眠障碍）的存在都可能导致气喘患者失眠。因此，气喘患者数量的增加预示着睡眠障碍治疗市场的扩大。根据世界卫生组织估计，2019年有4.55亿人死于气喘，2.62亿人受到气喘影响。根据气喘医学博士组织 (Asthma MD Organization) 的数据，在美国，气喘占急诊室就诊人数的 25%，每年有 200 万人次就诊。此外，根据酒精机制，酗酒会导致睡眠数量和品质出现问题，酗酒者经常失眠。例如，澳洲统计局估计，2020-21 年，18 岁以上的 500 万澳洲人（四分之一）的饮酒量将超过澳洲成人建议摄取量。我是。

市场机会

由于多种因素导致的睡眠障碍盛行率上升等成长要素为睡眠障碍治疗市场的扩张提供了巨大的机会。此外，透过各机构组织的众多宣传活动，提高人们对睡眠障碍负面影响的认识，也进一步推动了睡眠障碍治疗市场的发展，并提供了进入该市场的有利机会。过去 25 年来，睡眠基金会每年都会举办睡眠意识週 (R)。在睡眠意识週期间，基金会将共用人们过去一年睡眠状况的深入资料，强调充足睡眠的好处以及睡眠如何改善健康和福祉。我们提供基于证据的指导。此外，疾病预防控制中心还授予了 2021 年至 2024 年为期三年的津贴，重点用于扩大对阻塞型睡眠呼吸中止症中止症的教育和认识。此外，生活水准的提高和健康意识的提高也推动了睡眠障碍治疗市场的成长。

北美地区预计将大幅成长

预计在预测期内，北美地区将占据睡眠障碍治疗市场的很大份额。造成这一比例的因素包括对该疾病的认识提高、诊断率上升和忙碌的生活方式。根据美国心理学会（APA）的一项调查，2020年成年人的压力程度为5.0分，分数范围为1到10。过去两年，Z 世代成年人的压力水平略有上升，到 2020 年将达到 6.1。此外，辉瑞和克利夫兰诊所等主要市场领导的存在进一步促进了该地区睡眠障碍治疗市场的成长。

睡眠障碍治疗市场参与者

辉瑞正在推动医疗创新，让世界变得更健康。该公司提供 Sonata®（Zaleplon）胶囊 CIV 作为睡眠障碍的治疗药物。无论男女，从年轻人到老年人都可以服用。赛诺菲公司是一家跨国製药和医疗保健公司，总部位于巴黎。非昔硝唑是该公司与被忽视疾病药物倡议（DNDi）合作开发的口服药物，于2020年推出，是第一个治疗昏睡病的口服药物。武田製药是一家总部位于日本的研发全球製药公司。 Rozeram (TM) 是 FDA核准的非处方安眠药。它选择性地针对大脑 SCN 中存在的两种受体。

市场主要发展

2023年6月，瑞士公司Idorsia推出了治疗慢性失眠的革命性疗法QUIVIVIQ（dalidrexant）。它是瑞士核准的第一个双重Orexin受体拮抗，用于减少失眠症中的夜间多动性觉醒。 2022 年 9 月，沃克哈特医院在孟买中央布兰德开设了睡眠障碍诊所。我们治疗所有睡眠障碍，包括睡眠呼吸中止症、失眠、嗜睡、打鼾和睡眠呼吸中止呼吸中止症候群。 2021 年 12 月，韩国精神保健Start-UpsHoneynaps 宣布推出失眠治疗数位治疗业务，此外还监测、分析和诊断睡眠期间的生物讯号。该平台由用于诊断睡眠障碍的人工智慧软体 SOMNUM 提供支援。

目录

第一章简介

  • 市场概况
  • 市场定义
  • 调查范围
  • 市场区隔
  • 货币
  • 先决条件
  • 基准年和预测年时间表

第二章调查方法

  • 调查资料
  • 先决条件

第三章执行摘要

  • 研究亮点

第四章市场动态

  • 市场驱动因素
  • 市场抑制因素
  • 波特五力分析
  • 产业价值链分析

第五章睡眠障碍治疗市场：依药物类型

  • 介绍
  • 苯二氮平类
  • 非苯二氮平类药物
  • 抗忧郁症
  • Orexin拮抗剂
  • 褪黑激素拮抗剂
  • 其他类型的药物

第六章睡眠障碍治疗市场：依应用分类

  • 介绍
  • 失眠
  • 睡眠呼吸中止
  • 发作性睡病
  • 昼夜节律紊乱
  • 其他应用

第七章睡眠障碍治疗市场：按付款人

  • 介绍
  • 公共卫生保险
  • 私人健康保险

第八章睡眠障碍治疗市场：按地区

  • 介绍
  • 北美洲
    • 美国
    • 加拿大
    • 墨西哥
  • 南美洲
    • 巴西
    • 阿根廷
    • 其他的
  • 欧洲
    • 英国
    • 德国
    • 法国
    • 西班牙
    • 其他的
  • 中东/非洲
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 以色列
    • 其他的
  • 亚太地区
    • 日本
    • 中国
    • 印度
    • 韩国
    • 印尼
    • 泰国
    • 其他的

第九章竞争环境及分析

  • 主要企业及策略分析
  • 市场占有率分析
  • 合併、收购、协议和合作

第十章 公司简介

  • Dr Reddy's Laboratory
  • Merck & Co.
  • Pfizer
  • Sanofi SA
  • Takeda Pharmaceuticals Inc.
  • Teva Pharmaceuticals Inc.
  • Vanda Pharmaceuticals Inc.
  • Sleep Health Solutions
  • Cleveland Clinic
  • Mayo Clinic
简介目录
Product Code: KSI061615712

The sleep disorder treatment market is expected to grow at a CAGR of 10.99% from US$14.510 billion in 2021 to US$30.102 billion in 2028.

Many treatments are available for sleep disturbances, depending on the nature and underlying cause. However, it typically entails a mix of medical interventions and dietary adjustments. The higher prevalence of sleep disorders due to numerous underlying factors such as medication, frequent urination, and increasing depression disorder is driving the sleep disorder treatment market growth. Moreover, the growing alcohol consumption and increasing asthma cases are further expected to boost the sleep disorder treatment market.

Rising cases of sleep disorders

The rising cases of sleep disorders worldwide owing to various factors such as medications, frequent urination, and several others is a major growth driver in the sleep disorder treatment market. For instance, the World Economic Forum estimated that 62% of adults in 2019 globally felt they didn't get enough sleep at night. Moreover, in 2022, up to 70 million Americans suffered from a sleep issue as per the Sleep Association Organization. According to a Sleep Foundation survey conducted in 2022, 51.2% of short-sleepers claim that sleep issues run in their family. Moreover, insomnia is the most common sleep disorder in the US affecting around two-thirds of US adults as per the Sleep Doctor. The rising sleep disorder along with its adverse effects such as drowsiness and irritability is contemplated to boost the sleep disorder treatment market.

Growing Prevalence of Depression and Anxiety

Insomnia, or the difficulty of getting to sleep and staying asleep, is one of the typical symptoms of depression. Moreover, sleep disruptions can be brought on by psychological or physical trauma, metabolic issues, or other health issues. Therefore, the rising depression conditions among people are positively impacting the sleep disorder treatment market. An estimated 5% of adults' worldwide experience depression which equates to approximately 280 million people according to the WHO. In the United States, depression significantly contributes to death, morbidity, disability, and economic expenses. For instance, in 2020, 18.5% of U.S. adults reported ever receiving a diagnosis of depression according to the CDC.

Rising Asthma Cases and Alcohol Consumption

The stimulant effects of asthma drugs and the existence of other medical diseases, such as sleep disorders, may both contribute to insomnia in patients with asthma. The rising asthma cases thus, indicate the sleep disorder treatment market expansion. In 2019, 455 000 individuals died from asthma and an estimated 262 million people were affected by it according to the WHO. According to the Asthma MD Organization, with 2 million visits each year, asthma is responsible for 25% of all emergency room visits in the United States. Additionally, according to the Alcohol Organisation, alcohol abuse causes issues with both sleep quantity and quality, and alcoholics frequently experience insomnia the rising alcohol consumption poses a serious threat to sleep quality thereby propelling the sleep disorder treatment market. For instance, 5 million Australians aged 18 and older (one in four) consumed more alcohol than the recommended amount for adults in Australia in 2020-21 as per the Australian Bureau of Statistics.

Opportunities in the Market

The growth factors such as the higher prevalence of sleep disorders due to several factors provide an immense opportunity for sleep disorder treatment market expansion. Additionally, the increased awareness among people about the adverse effects of sleep disorders through numerous awareness programs organized by institutions is further propelling the sleep disorder treatment market thereby providing an opportunity to enter the market. Sleep Awareness Week® is organized by Sleep Foundation every year for the last 25 years. The foundation shares insightful data about how people have slept over the previous year and offers evidence-based guidance on the advantages of getting enough sleep and how it affects health and well-being during Sleep Awareness Week. Additionally, the CDC awarded a 3-year grant from 2021-2024 to focus on expanding education and awareness of obstructive sleep apnea. Furthermore, the rising living standards and health consciousness are also augmenting the sleep disorder treatment market growth.

North America is expected to grow significantly

The North American region is expected to hold a significant share of the sleep disorder treatment market during the forecast period. Various factors attributed to such a share are rising disease awareness and diagnosis rates, as well as busy lifestyles. Adults assessed their stress levels as 5.0 on a scale of 1 to 10 in 2020, according to a survey conducted by the American Psychological Association (APA). The last two years saw a minor increase in stress levels among Gen Z adults, and by 2020, it to reach 6.1. Moreover, the presence of major market leaders such as Pfizer, and Cleveland Clinic further aids the sleep disorder treatment market growth in the region.

Sleep Disorder Treatment Market Players

  • Pfizer advances in medical innovation to make the world a healthier place. Sonata® (zaleplon) capsule CIV is offered by the company for sleep disturbances. It can be taken by both men and women of the younger and elderly generations.
  • Sanofi SA, headquartered in Paris is a multinational pharmaceutical and healthcare company. The oral drug fexinidazole developed by the company in collaboration with the Drugs for Neglected Diseases initiative (DNDi) was launched in 2020 as the first all-oral treatment of sleeping sickness.
  • Takeda Pharmaceuticals is a global research and development-driven pharmaceutical company based out of Japan. Rozeram™ is FDA approved non-scheduled prescription sleep medication. It selectively targets two receptors in the brain SCN.

Key Market Developments

  • In June 2023, QUVIVIQ (daridorexant), a groundbreaking medication for chronic insomnia problems, was introduced by Idorsia in Switzerland. It is Switzerland's first approved dual orexin receptor antagonist that decreases nighttime overactive wakefulness in insomnia.
  • In September 2022, Wockhardt Hospitals launched a Sleep Disorder Clinic at Mumbai Central Brand. It is open to deal with all kinds of sleep disorders such as sleep apnea, insomnia, hypersomnia, snoring, parasomnia, and others.
  • In December 2021, a Korean mental healthcare startup, HoneyNaps announced the opening of a digital therapeutics business for the treatment of insomnia in addition to monitoring, analyzing, and diagnosing inter-sleep bio-signals. The platform is enabled with AI software for diagnosing sleep diseases named SOMNUM.

Segmentation:

By Drug Type

  • Benzodiazepines
  • Nonbenzodiazepines
  • Antidepressants
  • Orexin Antagonists
  • Melatonin Antagonists
  • Other Drug Types

By Application

  • Insomnia
  • Sleep Apnea
  • Narcolepsy
  • Circadian Disorders
  • Other Applications

By Payor

  • Public Health Insurance
  • Private Health Insurance

By Geography

  • North America
  • United States
  • Canada
  • Mexico
  • South America
  • Brazil
  • Argentina
  • Others
  • Europe
  • United Kingdom
  • Germany
  • France
  • Spain
  • Others
  • Middle East and Africa
  • Saudi Arabia
  • UAE
  • Israel
  • Others
  • Asia Pacific
  • Japan
  • China
  • India
  • South Korea
  • Indonesia
  • Thailand
  • Others

TABLE OF CONTENTS

1. INTRODUCTION

  • 1.1. Market Overview
  • 1.2. Market Definition
  • 1.3. Scope of the Study
  • 1.4. Market Segmentation
  • 1.5. Currency
  • 1.6. Assumptions
  • 1.7. Base, and Forecast Years Timeline

2. RESEARCH METHODOLOGY

  • 2.1. Research Data
  • 2.2. Assumptions

3. EXECUTIVE SUMMARY

  • 3.1. Research Highlights

4. MARKET DYNAMICS

  • 4.1. Market Drivers
  • 4.2. Market Restraints
  • 4.3. Porter's Five Force Analysis
    • 4.3.1. Bargaining Power of Suppliers
    • 4.3.2. Bargaining Power of Buyers
    • 4.3.3. Threat of New Entrants
    • 4.3.4. Threat of Substitutes
    • 4.3.5. Competitive Rivalry in the Industry
  • 4.4. Industry Value Chain Analysis

5. SLEEP DISORDER TREATMENT MARKET BY DRUG TYPE

  • 5.1. Introduction
  • 5.2. Benzodiazepines
  • 5.3. Nonbenzodiazepines
  • 5.4. Antidepressants
  • 5.5. Orexin Antagonists
  • 5.6. Melatonin Antagonists
  • 5.7. Other Drug Types

6. SLEEP DISORDER TREATMENT MARKET BY APPLICATION

  • 6.1. Introduction
  • 6.2. Insomnia
  • 6.3. Sleep Apnea
  • 6.4. Narcolepsy
  • 6.5. Circadian Disorders
  • 6.6. Other Applications

7. SLEEP DISORDER TREATMENT MARKET BY PAYOR

  • 7.1. Introduction
  • 7.2. Public Health Insurance
  • 7.3. Private Health Insurance

8. SLEEP DISORDER TREATMENT MARKET BY GEOGRAPHY

  • 8.1. Introduction
  • 8.2. North America
    • 8.2.1. United States
    • 8.2.2. Canada
    • 8.2.3. Mexico
  • 8.3. South America
    • 8.3.1. Brazil
    • 8.3.2. Argentina
    • 8.3.3. Others
  • 8.4. Europe
    • 8.4.1. United Kingdom
    • 8.4.2. Germany
    • 8.4.3. France
    • 8.4.4. Spain
    • 8.4.5. Others
  • 8.5. The Middle East and Africa
    • 8.5.1. Saudi Arabia
    • 8.5.2. UAE
    • 8.5.3. Israel
    • 8.5.4. Others
  • 8.6. Asia Pacific
    • 8.6.1. Japan
    • 8.6.2. China
    • 8.6.3. India
    • 8.6.4. South Korea
    • 8.6.5. Indonesia
    • 8.6.6. Thailand
    • 8.6.7. Others

9. COMPETITIVE ENVIRONMENT AND ANALYSIS

  • 9.1. Major Players and Strategy Analysis
  • 9.2. Market Share Analysis
  • 9.3. Mergers, Acquisitions, Agreements, and Collaborations

10. COMPANY PROFILES

  • 10.1. Dr Reddy's Laboratory
  • 10.2. Merck & Co.
  • 10.3. Pfizer
  • 10.4. Sanofi SA
  • 10.5. Takeda Pharmaceuticals Inc.
  • 10.6. Teva Pharmaceuticals Inc.
  • 10.7. Vanda Pharmaceuticals Inc.
  • 10.8. Sleep Health Solutions
  • 10.9. Cleveland Clinic
  • 10.10. Mayo Clinic